Abstract
Three of the major biochemical pathways implicated in the pathogenesis of hyperglycemia induced vascular damage (the hexosamine pathway, the advanced glycation end product (AGE) formation pathway and the diacylglycerol (DAG)–protein kinase C (PKC) pathway) are activated by increased availability of the glycolytic metabolites glyceraldehyde-3-phosphate and fructose-6-phosphate. We have discovered that the lipid-soluble thiamine derivative benfotiamine can inhibit these three pathways, as well as hyperglycemia-associated NF-κB activation, by activating the pentose phosphate pathway enzyme transketolase, which converts glyceraldehyde-3-phosphate and fructose-6-phosphate into pentose-5-phosphates and other sugars. In retinas of diabetic animals, benfotiamine treatment inhibited these three pathways and NF-κB activation by activating transketolase, and also prevented experimental diabetic retinopathy. The ability of benfotiamine to inhibit three major pathways simultaneously might be clinically useful in preventing the development and progression of diabetic complications.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications
Molecular Neurodegeneration Open Access 28 March 2022
-
Role of pyruvate in maintaining cell viability and energy production under high-glucose conditions
Scientific Reports Open Access 23 September 2021
-
Thiamine and diabetes: back to the future?
Acta Diabetologica Open Access 05 June 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout






References
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998).
Wei, M., Gaskill, S.P., Haffner, S.M. & Stern, M.P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 7, 1167–1172 (1998).
Nishikawa, T., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787–790 (2000).
Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001).
Du, X.L. et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. USA 97, 12222–12226 (2000).
Schenk, G., Duggleby, R.G. & Nixon P.F. Properties and functions of the thiamine diphosphate dependent enzyme transketolase. Int. J. Biochem. Cell Biol. 30, 1297–1318 (1998).
Saito, N., Kimura, M., Kuchiba, A. & Itokawa, Y. Blood thiamine levels in outpatients with diabetes mellitus. J. Nutr. Sci. Vitaminol. (Tokyo) 33, 421–430 (1987).
Loew, D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int. J. Clin. Pharmacol. Ther. 34, 47–50 (1996).
Pieper, G.M. & Haq, R.U. Activation of nuclear factor B in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J. Cardiovasc. Pharmacol. 30, 528–532 (1997).
Lukienko, P.I., Mel'nichenko, N.G., Zverinskii, I.V. & Zabarodskaya, S.V. Antioxidant properties of thiamine. Bull. Exp. Biol. Med. 9, 303–305 (2000).
Hammes, H.P. et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. USA 88, 11555–11559 (1991).
Ishii, H. et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272, 728–731 (1996).
Bitsch, R., Wolf, M., Moller, J., Heuzeroth, L. & Gruneklee, D. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamine derivative. Ann. Nutr. Metab. 35, 292–296 (1991).
Ascher, E. et al. Thiamine reverses hyperglycemia-induced dysfunction in cultured endothelial cells. Surgery 130, 851–858 (2001).
La Selva, M. et al. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 39, 1263–1268 (1996).
Stracke, H. et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp. Clin. Endocrinol. Diabetes 109, 330–336 (2001).
Stevens, V.J., Vlassara, H., Abati, A. & Cerami, A. Nonenzymatic glycosylation of hemoglobin. J. Biol. Chem. 252, 2998–3002 (1977).
Thornalley, P.J., Jahan, I. & Ng, R. Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J. Biochem. 129, 543–549 (2001).
Kaiser, N. et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42, 80–89 (1993).
Stepuro, I.I., Piletskaya, T.P., Stepuro, V.I. & Maskevich, S.A. Thiamine oxidative transformations catalyzed by copper ions and ascorbic acid. Biochemistry (Mosc.) 62, 1409–1414 (1997).
Koya, D. et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14, 439–447 (2000).
Soulis-Liparota, T., Cooper, M., Papazoglou, D., Clarke, B. & Jerums, G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40, 1328–1334 (1991).
Nakamura, S. et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46, 895–899 (1997).
Park, L. et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4, 1025–1031 (1998).
Rossetti, L. & Hu, M. Skeletal muscle glycogenolysis is more sensitive to insulin than is glucose transport/phosphorylation. Relation to the insulin-mediated inhibition of hepatic glucose production. J. Clin. Invest. 92, 2963–2974 (1993).
Shinohara, M. et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest. 101, 1142–1147 (1998).
Kurose, I. et al. CD18/ICAM-1-dependent oxidative NF-κB activation leading to nitric oxide production in rat Kupffer cells cocultured with syngeneic hepatoma cells. J. Clin. Invest. 99, 867–878 (1997).
Bierhaus, A. et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50, 2792–2808 (2001).
Hammes, H.P. et al. Acceleration of experimental diabetic retinopathy in the rat by omega-3 fatty acids. Diabetologia 39, 251–255 (1996).
Hammes, H.P., Bartmann, A., Engel, L. & Wulfroth, P. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia 40, 629–634 (1997).
Acknowledgements
We thank S. Hofmann for comments and suggestions and F. Scharpert for technical assistance. This work was supported in part by grants from the US National Institutes of Health, the Juvenile Diabetes Research Foundation, the American Diabetes Association, the Deutsche Forschungsgemeinschaft and Wörwag Pharma, GmbH & Co. KG (Böblingen, Germany).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hammes, HP., Du, X., Edelstein, D. et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9, 294–299 (2003). https://doi.org/10.1038/nm834
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm834
This article is cited by
-
Thioredoxin-Interacting Protein Inhibited Vascular Endothelial Cell–Induced HREC Angiogenesis Treatment of Diabetic Retinopathy
Applied Biochemistry and Biotechnology (2023)
-
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications
Molecular Neurodegeneration (2022)
-
Diabetischer Fuß: Fokus auf die Neuropathie
Info Diabetologie (2022)
-
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Nature Reviews Endocrinology (2021)
-
Role of pyruvate in maintaining cell viability and energy production under high-glucose conditions
Scientific Reports (2021)